Complete Response for Andexxa (andexanet) to convert accelerated approval to full approval to reverse the effects of direct-oral anticoagulants – AstraZeneca
AstraZeneca PLC’s anticoagulant reversal agent Andexxa (andexanet) will not convert to full approval, after the FDA issued a complete response letter for the supplemental biologics license application. The… read more.
